Cardiovascular Guidelines in Diabetics with Dr. George Bakris


The University of Chicago hypertension expert discusses new ADA recommendations for cardiovascular risk management.

Episode highlights

0:19 Intro
1:46 New ADA Guidelines
2:30 Introducing Dr. Bakris
3:25 The need for conservative guidelines
5:50 The cardiometabolic care collaboration
8:02 The trials that defined guidelines
11:50 How guideline decisions are made
15:30 The US - EU disparity in care
22:01 Navigating costly therapies
24:12 Introducing diet and exercise specialists
28:20 US healthcare’s hurdles in cardiovascular care
30:30 How COVID-19 influences the field
32:20 Wearable technology and telemedicine
34:26 Outro

The American Diabetes Association (ADA) recently published updated annual guidelines which provide clinicians perspective on diagnosing, screening, and managing hypertension and cardiovascular risks in patients with type 2 diabetes.

The guidelines, which feature collaborative perspective from the American College of Cardiology (ACC), serve as a point of reflection on all the various advances being made in treating comorbid cardiovascular risk among the growing diabetes population.

They also provide context on the comprehensive utility of drug classes such as GLP-1 agonists and SGLT-2 inhibitors, which have been increasingly investigated for various health outcomes in cardiometabolic patients for a decade now—and continue to be assessed for more benefits now.

There’s much to address in the single mention of the state of cardiometabolic care. The first DocTalk episode of the year aims to tackle all the facets of the new guidelines, and more.

In an interview with HCPLive, George Bakris, MD, professor of medicine and director of the Comprehensive Hypertension Center at the University of Chicago School of Medicine, shared perspective on the new ADA guidelines and trials which influenced it, the evolving cardiometabolic care team, and the current issues burdening the field at this moment.

Related Videos
What Should the American Academy of Physician Associates Focus on in 2025?
GLP-1 Agonist Safety Risks and Obesity Stigma with Kevin Peterson, MD, MPH
The Rising Rate of Heat-Related Illness, with Janelle Bludhorn, PA-C
Video 6 - "Evaluating Safety of Novel LDL Management Mechanism"
Video 5 - "Optimizing PCSK9 Inhibitors and Analyzing Plaque Reduction Data"
Video 4 - "Innovations in Small Interfering RNA (siRNA) Therapy"
Video 3 - "Ongoing Lp(a) Trials and Clinical Approaches to Treatment"
A panel of 5 experts on Cushing's syndrome
A panel of 5 experts on Cushing's syndrome
Roger S. McIntyre, MD: GLP-1 Agonists for Psychiatry?
© 2024 MJH Life Sciences

All rights reserved.